In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series D raises $25mm for Tethys; adds $23mm

Executive Summary

Tethys Bioscience, developer of the PreDx diabetes risk score test, raised $25mm in its Series D financing led by first-time backer Aeris Capital AG, which adds a board member. Other new investor Wasatch Advisors was joined by returning shareholders Mohr Davidow Ventures, Kleiner Perkins Caulfield & Byers, and Intel Capital. Money from the round will be used to expand commercialization activities for PreDx, which can determine patients who are at risk for developing Type II diabetes within five years.
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies